Literature DB >> 20975809

An update on activated protein C (xigris) in the management of sepsis.

Cesar Alaniz1.   

Abstract

Entities:  

Year:  2010        PMID： 20975809      PMCID： PMC2957744     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  22 in total

1.  Severe sepsis--a new treatment with both anticoagulant and antiinflammatory properties.

Authors:  M A Matthay
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

2.  Structural and energetic characteristics of the heparin-binding site in antithrombotic protein C.

Authors:  U Friedrich; A M Blom; B Dahlbäck; B O Villoutreix
Journal:  J Biol Chem       Date:  2001-04-20       Impact factor: 5.157

3.  Risks and benefits of activated protein C treatment for severe sepsis.

Authors:  H Shaw Warren; Anthony F Suffredini; Peter Q Eichacker; Robert S Munford
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

4.  Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.

Authors:  Peter Q Eichacker; Robert L Danner; Anthony F Suffredini; Xizhong Cui; Charles Natanson
Journal:  Crit Care Med       Date:  2005-10       Impact factor: 7.598

5.  Severe sepsis and therapy with activated protein C.

Authors:  Joseph E Parrillo
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

6.  Drotrecogin alfa (activated) in severe sepsis.

Authors:  Jan O Friedrich
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

7.  Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.

Authors:  Salmaan Kanji; Marc M Perreault; Clarence Chant; David Williamson; Lisa Burry
Journal:  Intensive Care Med       Date:  2007-02-15       Impact factor: 17.440

8.  Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock.

Authors:  Jean-Francois Dhainaut; Massimo Antonelli; Patrick Wright; Arnaud Desachy; Jean Reignier; Sylvain Lavoue; Julien Charpentier; Mark Belger; Michael Cobas-Meyer; Cornelia Maier; Mariano A Mignini; Jonathan Janes
Journal:  Intensive Care Med       Date:  2009-03-05       Impact factor: 17.440

9.  Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).

Authors:  Marcel Levi; Mitchell Levy; Mark D Williams; Ivor Douglas; Antonio Artigas; Massimo Antonelli; Duncan Wyncoll; Jonathan Janes; Frank V Booth; Dazhe Wang; David P Sundin; William L Macias
Journal:  Am J Respir Crit Care Med       Date:  2007-06-07       Impact factor: 21.405

10.  Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.

Authors:  Simon Finfer; V Marco Ranieri; B Taylor Thompson; Philip S Barie; Jean-François Dhainaut; Ivor S Douglas; Bengt Gårdlund; John C Marshall; Andrew Rhodes
Journal:  Intensive Care Med       Date:  2008-10-07       Impact factor: 17.440
View more
  6 in total

Review 1.  Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients.

Authors:  Arturo J Martí-Carvajal; Ivan Solà; Christian Gluud; Dimitrios Lathyris; Andrés Felipe Cardona
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 2.  Trauma is danger.

Authors:  Paul F Hwang; Nancy Porterfield; Dylan Pannell; Thomas A Davis; Eric A Elster
Journal:  J Transl Med       Date:  2011-06-15       Impact factor: 5.531

Review 3.  DAMPs and NETs in Sepsis.

Authors:  Naomi-Liza Denning; Monowar Aziz; Steven D Gurien; Ping Wang
Journal:  Front Immunol       Date:  2019-10-30       Impact factor: 7.561

4.  Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia Presenting Concomitantly With Purpura Fulminans: A Case Report.

Authors:  Giulio Ciprian
Journal:  Cureus       Date:  2022-01-13

Review 5.  Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease.

Authors:  Prajeeda M Nair; Matthew J Rendo; Kristin M Reddoch-Cardenas; Jason K Burris; Michael A Meledeo; Andrew P Cap
Journal:  Semin Hematol       Date:  2020-07-27       Impact factor: 3.851

6.  The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases.

Authors:  Domenico Acanfora; Chiara Acanfora; Marco Matteo Ciccone; Pietro Scicchitano; Alessandro Santo Bortone; Massimo Uguccioni; Gerardo Casucci
Journal:  Viruses       Date:  2021-09-23       Impact factor: 5.048
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.